3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Melanoma
19
Colorectal Neoplasms
11
Brain Neoplasms
7
Colonic Neoplasms
5
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Rectal Neoplasms
2
Lung Neoplasms
2
Thyroid Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphatic Metastasis
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Astrocytoma
1
Interventions
Cyclophosphamide
41
fludarabine
35
Tacrolimus
28
Mycophenolic Acid
27
Whole-Body Irradiation
25
Busulfan
24
fludarabine phosphate
21
Melphalan
19
thymoglobulin
16
Antilymphocyte Serum
16
Methotrexate
13
Thiotepa
12
Stem Cell Transplantation
9
Rituximab
9
Granulocyte Colony-Stimulating Factor
9
Filgrastim
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Nivolumab
5
ruxolitinib
4
merphos
4
Peripheral Blood Stem Cell Transplantation
4
Cytarabine
4
Cord Blood Stem Cell Transplantation
4
Bendamustine Hydrochloride
4
tocilizumab
3
itacitinib
3
fedratinib
3
dabrafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hematologic Neoplasms
×
encorafenib
×
Clear all
NCT01981187
2021-03-26
SIGNATURE
Pfizer
Phase 2
Terminated
12 enrolled
13 charts